August 12, 2025
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Read moreTogether,
we can reach higher ground
At Climb Bio, we believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients living with immune-mediated diseases.
August 12, 2025
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Read moreExperienced team
At Climb Bio, our team has a knack for seeing what no one else sees—and a drive to achieve results no one expects.
Elevating possibilities
Our pipeline is focused on immune-mediated diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases and CLYM116, an anti-APRIL antibody in IND-enabling studies for IgAN.
CANDIDATE
Budoprutug IV
Anti-CD19
Indications
Primary Membranous Nephropathy
Phase 2
Immune Thrombocytopenia
Phase 1
Systemic Lupus Erythematosus
Phase 1
CANDIDATE
Budoprutug SC
Anti-CD19
Indications
Autoimmune Disease
Phase 1
CANDIDATE
CLYM116*
Anti-APRIL
Indications
IgA Nephropathy
Pre-Clinical
Commitment to patients
We only have one life to live. At Climb, we all feel the urgency to give everyone living with an immune-mediated disease more quality time—and less time thinking of themselves as a patient.
Come climb with us
Here you’ll find good people. Smart people. Curious people. Our team has a diversified past, a singular focus on the now, and an unshakeable commitment to a better future.
OPEN POSITIONS: